Loading...
Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment
The mechanistic target of rapamycin (mTOR) is hyperactivated in many types of cancer, rendering it a compelling drug target; however, the impact of mTOR inhibition on metabolic reprogramming in cancer is incompletely understood. Here, by integrating metabolic and functional studies in glioblastoma m...
Na minha lista:
| Udgivet i: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Clinical Investigation
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4396477/ https://ncbi.nlm.nih.gov/pubmed/25798620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78239 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|